Guggenheim

National Gallery of Art Appoints Lena Stringari as Chief of Conservation

Retrieved on: 
Thursday, April 4, 2024
Gallery, International Foundation, Stringari, National Gallery, Science, Museum, Solomon, INCCA, Painting, University, Ethics, Research, History, Solomon R. Guggenheim, Guggenheim, National Gallery of Art, Conservation, Britain's Lost Masterpieces, Collection, Management

Washington, DC, April 04, 2024 (GLOBE NEWSWIRE) -- The National Gallery of Art announced today that Lena Stringari will join the museum as chief of conservation.

Key Points: 
  • Washington, DC, April 04, 2024 (GLOBE NEWSWIRE) -- The National Gallery of Art announced today that Lena Stringari will join the museum as chief of conservation.
  • In addition to preserving the nation’s art collection, the conservation division conducts innovative scientific research in collaboration with colleagues worldwide.
  • “We are excited to welcome Lena Stringari to the National Gallery of Art in this important leadership position,” said E. Carmen Ramos, chief curatorial and conservation officer.
  • She holds an MS in art conservation from the Winterthur Museum/University of Delaware and a BA in art history from the University of Pennsylvania.

Boundless Bio Announces Pricing of Initial Public Offering

Retrieved on: 
Wednesday, March 27, 2024
Biotechnology, Pharmaceutical, Oncology, General Health, Health, Genetics, Clinical Trials, Other Health, SVB Securities, Floor, Madison Avenue, Goldman Sachs, A-DNA, Telephone, Patient, DNA, Sale, Attention, Guggenheim, Security (finance), Biology, Guggenheim Partners, Prospectus, Nicollet Mall, State Street

Boundless Bio, Inc. (Nasdaq: BOLD), a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at an initial public offering price of $16.00 per share.

Key Points: 
  • Boundless Bio, Inc. (Nasdaq: BOLD), a clinical stage oncology company interrogating extrachromosomal DNA (ecDNA) biology to deliver transformative therapies to patients with previously intractable oncogene amplified cancers, today announced the pricing of its initial public offering of 6,250,000 shares of its common stock at an initial public offering price of $16.00 per share.
  • All of the shares are being offered by Boundless Bio.
  • The gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses, are expected to be $100.0 million.
  • In addition, Boundless Bio has granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Masdar to Acquire 50% Stake in Terra-Gen from Energy Capital Partners

Retrieved on: 
Tuesday, March 19, 2024
PJSC, Nicknames of Houston, ECP, Growth, White, Partnership, White & Case, JPMorgan Chase, LLP, Guggenheim, Wind, BMO Capital Markets, Covington & Burling, Latham & Watkins, Renewable energy

ECP, a leading investor across energy transition, electrification and decarbonization infrastructure assets, will fully exit its position in Terra-Gen in connection with the transaction.

Key Points: 
  • ECP, a leading investor across energy transition, electrification and decarbonization infrastructure assets, will fully exit its position in Terra-Gen in connection with the transaction.
  • Igneo Infrastructure Partners ("Igneo"), a global infrastructure investment manager, will retain its existing 50 percent stake in the company.
  • This transaction unites one of the largest independent renewable energy producers in the U.S. with Masdar – one of the fastest growing clean energy companies in the world.
  • John DiMarco, Managing Director at Igneo, said, "Igneo is excited to partner with Masdar on Terra-Gen's next phase of growth.

ADC Therapeutics to Participate in the Guggenheim 5th Annual Healthy Altitudes Summit

Retrieved on: 
Wednesday, March 6, 2024
Event, Webcast, Guggenheim, ADC

LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 5th Annual Healthy Altitudes Summit on Tuesday, March 12, at 7:30 a.m. MT.

Key Points: 
  • LAUSANNE, Switzerland, March 06, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) announced today that Ameet Mallik, Chief Executive Officer, will participate in a fireside chat at the Guggenheim 5th Annual Healthy Altitudes Summit on Tuesday, March 12, at 7:30 a.m. MT.
  • A live webcast of the presentation will be available via the Events & Presentations page in the Investors section of ADC Therapeutics’ website ir.adctherapeutics.com .
  • A replay of the webcast will be available for approximately 30 days.

Arcutis Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

Retrieved on: 
Monday, March 4, 2024
Varick Street, Attention, Mizuho, Lexington Avenue, Prospectus, Telephone, 2nd Floor, Floor, Sale, Exercise, Form, Morgan Stanley, Madison Avenue, Guggenheim, Needham & Company, Security (finance), Guggenheim Partners, Form S-3

WESTLAKE VILLAGE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the closing of its previously announced underwritten public offering of 18,157,895 shares of common stock at a public offering price of $9.50 per share, which includes 2,368,421 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions.

Key Points: 
  • WESTLAKE VILLAGE, Calif., March 04, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the closing of its previously announced underwritten public offering of 18,157,895 shares of common stock at a public offering price of $9.50 per share, which includes 2,368,421 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock at the public offering price, less underwriting discounts and commissions.
  • The total gross proceeds of the public offering were approximately $172.5 million, before deducting underwriting discounts and commissions and offering expenses payable by Arcutis.
  • All of the shares in the public offering were sold by Arcutis.
  • Morgan Stanley, TD Cowen, and Guggenheim Securities acted as joint lead bookrunning managers for the offering.

Culture ministers from around the world call for collective action to make culture a Sustainable Development Goal during inaugural MONDIACULT Ministerial Dialogue at Culture Summit Abu Dhabi

Retrieved on: 
Monday, March 4, 2024
UNESCO, Culture Summit Abu Dhabi, Artificial intelligence, Education, Assistant, Growth, Federal republic, Art Washington, Multilateralism, GCC, National Gallery, Government, Conference, NYU, SDG, Sustainable Development Goals, Republic, Guggenheim, Society, Summit, Tourism

ABU DHABI, United Arab Emirates, March 04, 2024 (GLOBE NEWSWIRE) -- Culture ministers from Spain, Morocco, Nigeria, Paraguay, Mauritius, Cabo Verde, Croatia, Cuba and Chad gathered today at the Culture Summit Abu Dhabi to inaugurate the first MONDIACULT Ministerial Dialogue, urging civil societies to take collaborative action and join the growing chorus of voices campaigning for culture to be recognised as a Sustainable Development Goal (SDG).

Key Points: 
  • Ernest Urtasun (Kingdom of Spain), HE Nina Obuljen Koržinek, (Croatia); Culture Summit Abu Dhabi 2024.
  • The dialogue, organised by the Department of Culture and Tourism – Abu Dhabi (DCT Abu Dhabi) and UNESCO, builds on the historic Declaration for Culture which was unanimously adopted by 150 states at the 2022 MONDIACULT summit.
  • For more information on Culture Summit Abu Dhabi, its full programme, and sessions available to watch online, please visit www.culturesummitabudhabi.com .
  • Culture Summit Abu Dhabi Press Kit, including imagery, is available here .

Arcutis Announces Pricing of $150 Million Public Offering

Retrieved on: 
Thursday, February 29, 2024
Varick Street, Attention, Mizuho, Lexington Avenue, Psoriasis, Prospectus, Telephone, Atopic dermatitis, 2nd Floor, Floor, Sale, Form, Morgan Stanley, Madison Avenue, Guggenheim, Needham & Company, S-3, Security (finance), Guggenheim Partners

WESTLAKE VILLAGE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of common stock.

Key Points: 
  • WESTLAKE VILLAGE, Calif., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT) a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the pricing of its underwritten public offering of common stock.
  • The shares of common stock are being sold at a public offering price of $9.50 per share.
  • All shares of common stock to be sold in the offering are being offered by Arcutis.
  • The gross proceeds to Arcutis from the offering are expected to be approximately $150.0 million, before deducting underwriting discounts and commissions and offering expenses payable by Arcutis and assuming no exercise of the underwriters’ option to purchase additional shares.

Arcutis Announces Proposed Public Offering

Retrieved on: 
Wednesday, February 28, 2024
Varick Street, Attention, Mizuho, Lexington Avenue, Prospectus, Telephone, 2nd Floor, Floor, Sale, Morgan Stanley, Madison Avenue, Guggenheim, Needham & Company, Guggenheim Partners, Security (finance)

All of the shares of common stock and pre-funded warrants in this offering are being sold by Arcutis.

Key Points: 
  • All of the shares of common stock and pre-funded warrants in this offering are being sold by Arcutis.
  • The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
  • In addition, Arcutis intends to grant the underwriters a 30-day option to purchase up to an additional $22.5 million of shares of its common stock at the public offering price per share.
  • Morgan Stanley, TD Cowen, and Guggenheim Securities are acting as joint lead bookrunning managers for the proposed offering.

Shu Lea Cheang Selected as the 2024 LG Guggenheim Award Recipient

Retrieved on: 
Monday, March 4, 2024
Desire, Museum, LG Corporation, NTT, Garlic, Venice Biennale, Fresh Kill, Singapore Art Museum, Art, Institute of Contemporary Art, Guggenheim, Organization, Biennial plant, Whitney Museum, Museum of Modern Art, Cheang, UKI, LG Electronics, Solomon R. Guggenheim Museum, Machine learning, Whitney Biennial, LG, Software design, Solomon, Bowling alley, Solomon R. Guggenheim, NTT InterCommunication Center, Society, Hammer Museum, Research, Castle of Rivoli, Brand management, Taipei Fine Arts Museum, Communication, Documenta 14, Walker Art Center, Science, Interior design

SEOUL, South Korea, March 4, 2024 /PRNewswire/ -- The Solomon R. Guggenheim Museum and LG proudly announce Shu Lea Cheang as the 2024 LG Guggenheim Award recipient.

Key Points: 
  • SEOUL, South Korea, March 4, 2024 /PRNewswire/ -- The Solomon R. Guggenheim Museum and LG proudly announce Shu Lea Cheang as the 2024 LG Guggenheim Award recipient.
  • "Shu Lea Cheang was one of the first to recognize the liberatory potential of the digital realm.
  • "LG is delighted to join the Guggenheim in honoring Shu Lea Cheang with the second LG Guggenheim Award.
  • LG commends the award jury's recognition of Shu Lea Cheang's daring foresight," states Seol Park, Head of Brand Management at LG Corp.
    Cheang (b.

Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

Retrieved on: 
Friday, February 16, 2024
Attention, Prospectus, Telephone, Floor, Sale, Exercise, Form, State Street, SVB Securities, Therapy, Madison Avenue, Guggenheim, Security (finance), Guggenheim Partners, Research

The aggregate gross proceeds to Larimar from this offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $172.5 million.

Key Points: 
  • The aggregate gross proceeds to Larimar from this offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $172.5 million.
  • Leerink Partners, Citigroup and Guggenheim Securities acted as joint bookrunning managers for the offering.
  • LifeSci Capital acted as lead manager for the offering.
  • The shares were offered pursuant to a shelf registration statement on Form S-3 (File No.